Other autoimmune hemolytic anemias
ICD-10 D59.1 is a billable code used to indicate a diagnosis of other autoimmune hemolytic anemias.
Other autoimmune hemolytic anemias (AIHA) represent a group of disorders characterized by the immune system mistakenly attacking and destroying red blood cells, leading to anemia. This condition can be classified into warm and cold AIHA, depending on the temperature at which the antibodies react. Warm AIHA is often associated with conditions such as lymphoproliferative disorders, autoimmune diseases, and certain infections, while cold AIHA is typically linked to cold agglutinin disease and infections like Mycoplasma pneumoniae. Patients may present with symptoms such as fatigue, pallor, jaundice, and splenomegaly. Diagnosis is confirmed through laboratory tests, including a complete blood count (CBC), reticulocyte count, direct Coombs test, and peripheral blood smear. Treatment options vary based on the underlying cause and severity of the anemia, ranging from corticosteroids and immunosuppressive therapies to splenectomy and blood transfusions. Understanding the nuances of AIHA is crucial for accurate coding and effective patient management.
Detailed lab results, including CBC, reticulocyte count, and Coombs test results.
Diagnosis and management of AIHA, monitoring treatment response.
Ensure accurate documentation of the type of AIHA and any associated conditions.
Comprehensive patient history, physical examination findings, and treatment plans.
Evaluation of anemia in patients with autoimmune disorders.
Documenting the patient's overall health status and any comorbidities.
Used to evaluate anemia and monitor treatment response.
Document the reason for the test and any relevant clinical findings.
Hematology specialists should ensure comprehensive lab documentation.
Warm AIHA involves antibodies that react at body temperature, often associated with autoimmune diseases, while cold AIHA involves antibodies that react at lower temperatures, typically linked to infections or certain malignancies.
